Associated Papers
APF2: an improved ensemble method for pharmacogenomic variant effect prediction.
Zhou Y et al.
The Pharmacogenomics Journal, 2024
38802404 (PubMed )
Supplement: 41397_2024_338_MOESM2_ESM.xlsx › Sheet1
An optimized prediction framework to assess the functional impact of pharmacogenetic variants.
Zhou Y et al.
The Pharmacogenomics Journal, 2019
30206299 (PubMed )
Supplement: 41397_2018_44_MOESM5_ESM.xlsx › Sheet1
Genetic architecture differences between pediatric and adult-onset inflammatory bowel diseases in the Polish population.
Ostrowski J et al.
Scientific Reports, 2016
28008999 (PubMed )
Supplement: srep39831-s2.xls › _Table_S6
Polymorphisms and disease: hotspots of inactivation in methyltransferases.
Rutherford K et al.
Trends in Biochemical Sciences, 2010
Human phenylethanolamine N-methyltransferase genetic polymorphisms and exercise-induced epinephrine release.
Ji Y et al.
Physiological Genomics, 2008
Human phenylethanolamine N-methyltransferase pharmacogenomics: gene re-sequencing and functional genomics.
Ji Y et al.
Journal of Neurochemistry, 2005
Identification of 197 genetic variations in six human methyltranferase genes in the Japanese population.
Saito S et al.
Journal of Human Genetics, 2001
Insights into S-adenosyl-l-methionine (SAM)-dependent methyltransferase related diseases and genetic polymorphisms.
Li J et al.
Mutation Research. Reviews in Mutation Research, 0
Select a paper to view details